3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
4
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
7
Sarcoma
6
Prostatic Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Lung Neoplasms
3
Liposarcoma, Myxoid
3
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Sarcoma, Synovial
2
Neurofibrosarcoma
2
Melanoma
2
Liposarcoma
2
Leiomyosarcoma
2
Histiocytoma, Malignant Fibrous
2
Fibrosarcoma
2
Carcinoma, Intraductal, Noninfiltrating
2
Advanced Refractory Solid Tumors
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thymoma
1
Small Cell Lung Cancer Limited Stage
1
Sarcoma, Clear Cell
1
Sarcoma, Alveolar Soft Part
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Myosarcoma
1
Lymphatic Metastasis
1
Lymphangiosarcoma
1
Locally Recurrent Rectal Cancer
1
Interventions
Cisplatin
68
Paclitaxel
32
Radiotherapy
31
Carboplatin
23
Bevacizumab
21
pembrolizumab
20
Brachytherapy
18
atezolizumab
11
camrelizumab
10
Nivolumab
10
Gemcitabine
10
Drug Therapy
9
tislelizumab
8
Topotecan
8
Taxes
8
Chemoradiotherapy
8
Radiation
7
Docetaxel
7
Albumin-Bound Paclitaxel
7
zimberelimab
6
toripalimab
6
nimotuzumab
6
Magnetic Resonance Spectroscopy
6
Cetuximab
6
lenvatinib
5
durvalumab
5
dostarlimab
5
Platinum
5
Papillomavirus Vaccines
5
Injections
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Uterine Cervical Neoplasms
×
Radiation Dose Hypofractionation
×
Clear all
NCT07276360
2026-03-27
HypoRTCx-UG
Uganda Cancer Institute
Phase 2
Recruiting
278 enrolled